Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 18 Source: CRO
- €839.5 million turnover
-
€95.8 million
profit - 684 employees
-
31st Dec 17 Source: CRO
- €981.7 million turnover
-
€272.6 million
profit - 615 employees
- 11 more years available »
Ranking
By Turnover
(€839.5 million)- 111th in Top Companies
- 14th in Pharma
By Employees
(684)- 285th in Top Companies
- 23rd in Pharma
-
- 684
- €839.5 million
Employees
- Johannes Schweppenhäuser Country Manager
Latest News
- Feb 27 Plan to restart air travel needs long-term preparation to begin taking off
- Feb 27 Element Finance targets SaaS companies seeking growth capital
- Feb 27 Dermot Desmond-backed diamond mine set to reopen after Covid-19 outbreak
- Feb 27 Maughan family group bought Irish Opel franchise for €9.5m
- Feb 26 Global rules on taxing tech firms move closer as US drops Trump-era objection